The impact of EGFRi on glycolysis was further confirmed by the Heath group in 2015, who reported, as assessed by the 18F–FDG radioassay, a reduction of consumption of glucose and hexokinase activity following erlotinib treatment in patient-derived glioblastoma (GBM) neurosphere tumor cells (GBM39) that express EGFR [31]. The gene discussed is EGFR; the disease is glioblastoma.